Table 2.

Differential gene expression between DLBCL patients with different disease stages at baseline

	EGR-1		T-bet		GATA-3		TGF-β
	ΔΔCt 1	2 -ΔΔCt1	ΔΔCt 1	2 -ΔΔCt1	ΔΔCt 1	2 -ΔΔCt1	ΔΔCt 2	2 -ΔΔCt2
Stage I-II	−0.120 ± 0.67	1.09 ± 0.23	−2.496 ± 0.568	5.65 ± 1.05	−3.742 ± 0.714	13.33 ± 2.65	0.723 ± 0.793	0.605 ± 0.51
Stage III-IV	−2.952 ± 0.851	7.69 ± 2.10	−4.099 ± 1.272	17.24 ± 4.23	−5.143 ± 1.632	35.71 ± 12.41	1.337 ± 0.931	0.395 ± 0.46
P	0.008*		0.068		0.144		0.092

Note: ΔΔCt¹ = ΔCt_{target gene in control}-ΔCt_{target gene in patients},2^-ΔΔCt1 indicates the fold decrease in the expression of target genes in patients compared to controls. ΔΔCt² = ΔCt _{TGF-β in patient}-ΔCt _{TGF-β in control,} 2^-ΔΔCt2 indicates the fold increase in TGF-β expression in patients compared to controls. *indicates that there is significant difference between two groups.